Medtronic

MDT Health Care Market cap $120B as of Sep 14, 2026 16:00 ET S&P 500

Q1 FY27 Apr 25 – Jul 31, 2026 reported Sep 3, 2026

Revenue$9.8B +14% year over year

Gross profit$6.3B 65% margin

Operating profit$1.8B 18% margin

Net profit$1.5B 15% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q1 FY27 (period ends Jul 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	9.8	100%	+14%
Cost of revenue	−3.4	35%
Gross profit	6.3	65% margin	+0pp
SG&A	−3.2	33%	+0pp
Other	−1.4	14%	+0pp
Operating profit	1.8	18% margin	+1pp
Tax	−0.3
Net profit	1.5	15% margin	+3pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY26 (period ends Apr 24, 2026).
Item	Value	Share of revenue	Year over year
Revenue	9.81	100%	+10%
Cardiovascular	3.80	39%	+14%
Neuroscience group	2.75	28%	+5%
Medical surgical	2.39	24%	+8%
Diabetes group	0.84	9%	+15%
Other and unallocated	0.04	0%
Cost of revenue	−3.40	35%
Gross profit	6.41	65% margin	+1pp
SG&A	−3.06	31%	+1pp
Other	−1.48	15%	+0pp
Operating profit	1.87	19% margin	+3pp
Interest & other costs	−0.05
Tax	−0.58
Net profit	1.24	13% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY26 (period ends Jan 23, 2026).
Item	Value	Share of revenue	Year over year
Revenue	9.02	100%	+9%
Cardiovascular	3.46	38%	+14%
Neuroscience group	2.56	29%	+4%
Medical surgical	2.17	24%	+5%
Diabetes group	0.80	9%	+15%
All other	0.03	0%	+0%
Cost of revenue	−3.26	36%
Gross profit	5.76	64% margin	−3pp
SG&A	−2.96	33%	+0pp
Other	−1.34	15%	+0pp
Operating profit	1.46	16% margin	−4pp
Interest & other costs	−0.07
Tax	−0.25
Net profit	1.14	13% margin	−3pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Oct 24, 2025).
Item	Value	Share of revenue	Year over year
Revenue	8.96	100%	+7%
Cardiovascular	3.44	38%	+11%
Neuroscience group	2.56	29%	+5%
Medical surgical	2.17	24%	+2%
Diabetes group	0.76	9%	+10%
All other	0.04	0%	−5%
Cost of revenue	−3.06	34%
Gross profit	5.90	66% margin	+1pp
SG&A	−2.97	33%	+0pp
Other	−1.25	14%	+0pp
Operating profit	1.69	19% margin	+0pp
Interest & other costs	−0.10
Tax	−0.22
Net profit	1.37	15% margin	+0pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Jul 25, 2025).
Item	Value	Share of revenue	Year over year
Revenue	8.6	100%	+8%
Medical surgical	2.1	24%
Cardiac rhythm	1.7	20%
Cranial	1.2	14%
Structural heart & aortic	0.9	11%
Diabetes	0.7	8%
Specialty therapies	0.7	8%
Coronary	0.6	8%
Other revenue	0.6	7%
Cost of revenue	−3.0	35%
Gross profit	5.6	65% margin	+0pp
SG&A	−2.8	33%	−1pp
Other	−1.3	15%	+0pp
Operating profit	1.4	17% margin	+1pp
Interest & other costs	−0.2
Tax	−0.3
Net profit	1.0	12% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q1 FY27 Apr 25 – Jul 31, 2026 reported Sep 3, 2026 Operating margin 18% Net profit $1.5B	Apr 25 – Jul 31, 2026	Sep 3, 2026	$9.76B	+14%	18%	$1.5B	15%
Q4 FY26 Jan 24 – Apr 24, 2026 reported Jun 18, 2026 Operating margin 19% Net profit $1.2B	Jan 24 – Apr 24, 2026	Jun 18, 2026	$9.81B	+10%	19%	$1.2B	13%
Q3 FY26 Oct 25, 2025 – Jan 23, 2026 reported Feb 24, 2026 Operating margin 16% Net profit $1.1B	Oct 25, 2025 – Jan 23, 2026	Feb 24, 2026	$9.02B	+9%	16%	$1.1B	13%
Q2 FY26 Jul 26 – Oct 24, 2025 reported Nov 25, 2025 Operating margin 19% Net profit $1.4B	Jul 26 – Oct 24, 2025	Nov 25, 2025	$8.96B	+7%	19%	$1.4B	15%
Q1 FY26 Apr 26 – Jul 25, 2025 reported Aug 26, 2025 Operating margin 17% Net profit $1.0B	Apr 26 – Jul 25, 2025	Aug 26, 2025	$8.58B	+8%	17%	$1.0B	12%